Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.502    -0.074 (-12.85%)
Bid:
0.502
Ask:
0.70
Spread: 0.198 (39.442%)
Market Cap: £2.92m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Correction - Block Listing Update

25 Nov 2016 17:25

RNS Number : 2276Q
Futura Medical PLC
25 November 2016
 

The following amendment has been made to the Block Listing Update announcement released on 25 November 2016 at 15:05 under RNS No 2178Q.

The balance under the scheme(s) of securities not yet issued at the end of the period has been corrected to 2,520,462.

All other details remain unchanged. The full amended text is shown below.

 

 

 

25 November 2016

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Block Listing Update

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology makes the following amended update on its block listing, pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies. All figures relate to options over ordinary shares of 0.2 pence each.

The table below provides further detail.

 

Name of company:

Futura Medical plc

Name of scheme:

Unapproved Share Option Scheme ("USOS")EMI Share Option Scheme ("EMI")

Period of return:

From:

20 May 2016

To:

24 November 2016

Number and class of securities not issued under the scheme(s)

USOS:

1,440,600

EMI:

1,344,141

Total:

2,784,741

 

Number of securities issued under the scheme(s) during the period

 

 

Number of securities lapsed under the scheme(s) during the period (EMI adjustment to May return)

USOS:

Nil

EMI:

 

 

USOS:

EMI:

 

Nil

 

 

(284,279)

20,000

 

Balance under the scheme(s) of securities not yet issued at the end of the period (EMI adjustment to May return)

USOS:

1,156,321

EMI:

1,364,141

Total:

2,520,462

Number and class of securities originally admitted and the date of admission

USOS:

814,424 on 25 May 2011 and 1,202,280 on 8 October 2013

USOS Total:

2,016,704

EMI:

1,520,576 on 25 May 2011 and 1,467,720 on 8 October 2013

EMI Total:

2,988,296

Total:

5,005,000

 

Name of contact:

Derek Martin, Chief Financial Officer

Telephone number of contact:

+44 (0) 1483 685 670

 

 

For further information please contact:

 

Futura Medical plc

 

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

 

N+1 Singer (Nominated Adviser and Broker)

 

Aubrey Powell / Liz Yong

Corporate Finance

 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

 

Buchanan

 

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRAKPDDOBDDADB
Date   Source Headline
20th Sep 20184:35 pmRNSPrice Monitoring Extension
19th Sep 20189:05 amRNSSecond Price Monitoring Extn
19th Sep 20189:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSBusiness Update
29th Aug 20187:00 amRNSNotice of Interim Results
23rd Jul 20187:00 amRNSTPR 100: UK Regulatory Submission
13th Jun 20186:22 pmRNSResult of AGM
13th Jun 20187:00 amRNSAGM Statement
31st May 20186:20 pmRNSTotal Voting Rights
30th May 201810:20 amRNSBlock Listing Interim Review
25th May 20187:00 amRNSApplication for Block Listing
27th Apr 20185:11 pmRNSNotification of Major Interest in Shares
26th Apr 20187:00 amRNSPhase III efficacy study of MED2002
25th Apr 20187:00 amRNSPositive data from MED2002 PK study
6th Apr 201812:13 pmRNSNotice of AGM
14th Mar 20187:00 amRNSPreliminary Results
13th Mar 20187:00 amRNSPositive Interim Data from MED2002 PK study
20th Feb 20187:00 amRNSDirectorate Changes
15th Feb 20187:00 amRNSNotification of Preliminary Results
31st Jan 201810:39 amRNSTotal Voting Rights
4th Jan 20187:00 amRNSPublication of Positive MED2002 Clinical Data
3rd Jan 20183:08 pmRNSDirector/PDMR Shareholding
2nd Jan 20183:50 pmRNSRemuneration of Non-Executive Directors and TVR
29th Nov 20177:00 amRNSMED2002: Regulatory, Clinical & Commercial Update
29th Nov 20177:00 amRNSMED2002: PK Study Commences
24th Nov 20171:08 pmRNSBlock Listing Update
23rd Oct 20173:30 pmRNSPDMR Dealing
16th Oct 20177:00 amRNSFurther Positive Market Research Data for MED2002
13th Sep 20177:00 amRNSDirectors' / PDMR Dealing and Grant of Options
12th Sep 20177:00 amRNSInterim Results
1st Sep 201712:24 pmRNSNotification of Major Interest in Shares
23rd Aug 201710:32 amRNSCSD500: Termination of Licensing Agreement
22nd Aug 20173:59 pmRNSNotification of Half Year Results
4th Jul 20177:00 amRNSInvestor Presentation on MED2002
14th Jun 20175:00 pmRNSResult of AGM
14th Jun 20177:00 amRNSAGM Statement
31st May 20177:00 amRNSMED2002 Regulatory Update
31st May 20177:00 amRNSTotal Voting Rights
22nd May 20177:00 amRNSBlock Listing Update
20th Apr 20179:45 amRNSNotice of AGM
4th Apr 201712:11 pmRNSNotification of Major Interest in Shares
4th Apr 201712:10 pmRNSNotification of Major Interest in Shares
23rd Mar 20177:00 amRNSPreliminary Results
22nd Mar 20177:00 amRNSLicenses CSD500 in Portugal
6th Mar 20177:00 amRNSResearch Confirms MED2002's US$1 Billion Potential
6th Mar 20177:00 amRNSMED2002 Additional Patent Filing
23rd Jan 20171:00 pmRNSNotice of Preliminary Results
18th Jan 20174:30 pmRNSDirector's dealings
13th Jan 20175:45 pmRNSDirector / PDMR Dealing and Grant of Options
12th Jan 20173:00 pmRNSDirector / PDMR Dealing and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.